BioCentury
ARTICLE | Company News

SemBioSys, Avac Ltd. deal

April 14, 2008 7:00 AM UTC

Under a 2006 deal to develop SemBioSys' safflower-produced insulin program, SemBioSys received a $350,000 milestone payment from Avac for completing technical objectives, including starting a preclinical toxicology study. The company has now received $873,000 in total payments under that deal. SemBioSys plans to begin a Phase I/II trial of its safflower-derived insulin this year. ...